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Abstract: Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal 
and extra-intestinal symptoms related to the ingestion of gluten-containing food, in 
subjects that are not affected by either celiac disease or wheat allergy. Given the lack of a 
NCGS biomarker, there is the need for standardizing the procedure leading to the diagnosis 
confirmation. In this paper we report experts’ recommendations on how the diagnostic 
protocol should be performed for the confirmation of NCGS. A full diagnostic procedure 
should assess the clinical response to the gluten-free diet (GFD) and measure the effect of 
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a gluten challenge after a period of treatment with the GFD. The clinical evaluation is 
performed using a self-administered instrument incorporating a modified version of the 
Gastrointestinal Symptom Rating Scale. The patient identifies one to three main symptoms 
that are quantitatively assessed using a Numerical Rating Scale with a score ranging from 1 
to 10. The double-blind placebo-controlled gluten challenge (8 g/day) includes a one-week 
challenge followed by a one-week washout of strict GFD and by the crossover to the 
second one-week challenge. The vehicle should contain cooked, homogeneously 
distributed gluten. At least a variation of 30% of one to three main symptoms between the 
gluten and the placebo challenge should be detected to discriminate a positive from a 
negative result. The guidelines provided in this paper will help the clinician to reach a firm 
and positive diagnosis of NCGS and facilitate the comparisons of different studies, if 
adopted internationally. 
Keywords: non-celiac gluten sensitivity; diagnosis; double-blind placebo-controlled 
challenge; gastrointestinal symptom rating scale; irritable bowel syndrome 
 
1. Introduction 
Non-Celiac Gluten Sensitivity (NCGS) is a syndrome characterized by intestinal and extra-intestinal 
symptoms related to the ingestion of gluten-containing food, in subjects that are not affected by either 
celiac disease (CD) or wheat allergy (WA) [1,2]. The terminology “NCGS” is still a matter of debate. 
Although NCGS is triggered by gluten-containing cereals, the offending dietary protein has not been 
identified yet, and could include component/s that are different from gluten itself, e.g., the cereal 
protein amylase-trypsin inhibitors (ATIs) [3]. Then the terminology “NCGS” could be changed into 
“Non Celiac Wheat Sensitivity” (NCWS) in the near future, although this would exclude other relevant 
cereals like barley and rye. The prevalence of NCGS is not clearly defined yet. Indirect evidence 
suggests that NCGS is more common than CD [4], the latter affecting around 1% of the general 
population [5]. Treatment of NCGS is based on the celiac-type gluten-free diet (GFD) although it is 
unknown if long-term, strict avoidance of all gluten-related products is necessary. Since NCGS may be 
transient, gluten tolerance needs to be re-assessed in patients with NCGS [6]. 
Clinical presentation of NCGS might be multi-systemic and there have been a range of signs and 
symptoms reported in association with this condition (Table 1) [7]. The latency between gluten ingestion 
and the appearance of symptoms is usually short, within hours or days. Common features of NCGS are 
symptoms usually diagnosed under the umbrella of the irritable bowel syndrome (IBS), e.g., bloating, 
abdominal pain and irregular bowel movements [4]. Recent clinical studies have opened new insight into 
the etiology of these symptoms and the current literature suggests that many of the patients previously 
known under IBS are in fact intolerant to something they eat. Most common food reactions have been 
reported to gluten, lactose, milk protein and Fermentable Oligo, Di, and Monosaccharides And Polyols 
(FODMAPs) [8,9]. NCGS patients, however, often report symptoms outside of the intestinal tract, e.g., 
headache and/or foggy mind [4], which cannot be accounted for by lactose, and/or  
FODMAPs intolerance. 
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Table 1. The clinical manifestations of Non-Celiac Gluten Sensitivity (NCGS). 
Frequency Intestinal Extra-Intestinal 
Very Common Bloating Lack of wellbeing 
 Abdominal pain Tiredness 
Common Diarrhea Headache 
 Epigastric pain Anxiety 
 Nausea Foggy mind 
 Aerophagia Numbness 
 GER Joint/muscle pain 
 Aphthous stomatitis Skin rash/dermatitis 
 Alternating bowel habits  
 Constipation  
Undetermined Hematochezia Weight loss 
 Anal fissures Anemia 
  Loss of balance 
  Depression 
  Rhinitis/asthma 
  Weight increase 
  Interstitial cystitis 
  Ingrown hairs 
  Oligo or polymenorrhea 
  Sensory symptoms 
  Disturbed sleep pattern 
  Hallucinations 
  Mood swings 
  Autism 
  Schizophrenia 
In recent years, several studies explored the relationship between the ingestion of gluten-containing 
food and the appearance of neurological and psychiatric disorders/symptoms like ataxia, peripheral 
neuropathy, schizophrenia, autism, depression, anxiety, and hallucinations [10–14]. One of the 
hypothesized links between the gut and the brain (i.e., the brain-gut axis) postulates the existence of an 
increased intestinal permeability, also referred to as the “leaky gut syndrome” [15]. This in turn could 
allow gluten peptides (or other wheat-derived proteins) to cross the gut barrier, enter the bloodstream, 
and cross the blood-brain barrier, either causing neuro-inflammation or affecting the endogenous 
opiate system and neurotransmission within the nervous system. Food-induced modifications could 
also target the brain through the microbiota-brain-gut axis where the vagus is also a key element [16]. It 
should however be stressed that the possible relationship between NCGS and certain neuro-psychiatric 
disorders such as autism and schizophrenia is still far from clear. Furthermore, the cause/effect 
relationship between gluten ingestion and neuropsychiatric disorders, in terms of time latency, may be 
particularly difficult to ascertain. 
NCGS should not be an exclusion diagnosis only. There is an increasing need for standardizing the 
procedure leading to the confirmation of suspected NCGS. Ideally we should have a clear diagnosis 
before starting treatment, however such certainty is not always possible. In clinical medicine this 
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uncertainty can be resolved by using the treatment as the test that confirms the diagnosis. For example, if 
we are unsure if a patient’s airway obstruction has a reversible element, a trial of steroids can test this: a 
sufficient response is then considered evidence of reversibility [17]. Likewise the strategy of “test of 
treatment” with the GFD can be used to diagnose NCGS. 
On 6–7 October 2014, the 3rd International Expert Meeting on Gluten Related Disorders was held in 
Salerno, Italy, to reach a consensus on how the diagnosis of NCGS should be confirmed. It was 
acknowledged that in the absence of sensitive and specific biomarkers, a close and standardized 
monitoring of the patient during elimination and re-introduction of gluten is the most specific diagnostic 
approach and hence could be used as the diagnostic hallmark of NCGS. In this paper we report the 
experts’ agreement and recommendations on how the diagnostic protocol should be performed for the 
confirmation of NCGS. 
2. NCGS Diagnostic Protocol 
The diagnosis of NCGS should be considered in patients with persistent intestinal and/or  
extra-intestinal complaints showing a normal result of the CD and WA serological markers on a  
gluten-containing diet, usually reporting worsening of symptoms after eating gluten-rich food. The aim 
of the confirmation of the diagnosis of NCGS should be twofold: (1) assessing the clinical response to 
the GFD; (2) measuring the effect of reintroducing gluten after a period of treatment with the GFD.  
It follows that a full diagnostic evaluation, including Step 1 and 2 (see below), can only be started in the 
patient who is on a normal, gluten-containing diet. Unfortunately many of these patients are already on 
the GFD when first seen at the specialty clinic. A simplified/shortened diagnostic procedure, including 
only Step 2, may be adopted in these patients. 
In both Step 1 and Step 2, the clinical evaluation is performed using a self-administered instrument 
incorporating a modified version of the Gastrointestinal Symptom Rating Scale (GSRS). The GSRS is a 
disease-specific instrument, based on reviews of gastrointestinal symptoms and clinical experience, 
which has been widely used to evaluate common symptoms of gastrointestinal disorders [18]. The 
instrument presented here includes also items evaluating the extra-intestinal NCGS manifestations. 
Further items can be included under the box “other” in patients presenting with different symptoms. The 
patient identifies one to three main symptoms that will be quantitatively assessed using a Numerical 
Rating Scale (NRS) with a score ranging from 1 (mild) to 10 (severe) (Table 2 and Figure 1). 
2.1. Step 1: Definition of a Patient Responsive to the GFD (Patient on a Gluten-Containing Diet) 
Patients suspected of suffering from a gluten-related disorder should preliminarily undergo a full 
clinical and laboratory evaluation to exclude CD and WA while still on a gluten-containing diet, 
according to a previously outlined diagnostic protocol [19]. 
The following steps establish responsiveness to the GFD:  
1. At baseline the patient has to be on a normal gluten containing diet for at least six weeks.  
The patient is assessed by the Table 2 diagnostic questionnaire at week-2, -1 and 0 to establish 
baseline symptoms; 
2. At time 0 the GFD is started after detailed explanation (preferably by a dietitian); 
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3. Timeline: at least six weeks of verified GFD. Although the amelioration of symptoms is 
expected shortly after starting the GFD, a prolonged observation is needed to properly 
investigate the causal relationship, particularly for fluctuating symptoms (e.g., headache); 
4. Data recording: weekly completion of the Table 2 questionnaire from week 0 to 6. The patient 
will identify one to three main symptoms. The response parameters are those with an initial 
score of at least 3 on the numerical rating scale (NRS). 
The response is assessed for each parameter separately. A symptomatic response is a decrease of at 
least 30% of the baseline score. Responders are defined as patients who fulfill the response criteria 
(>30% reduction of one to three main symptoms or at least 1 symptom with no worsening of others) for 
at least 50% of the observation time (i.e., at least three of six weekly evaluations). 
The diagnosis of NCGS is excluded in subjects failing to show symptomatic improvement after  
six weeks of GFD. GFD-unresponsive patients should be investigated for other possible causes of  
IBS-like symptoms, e.g., intolerance to FODMAPs or small bowel bacterial overgrowth. 
Table 2. Questionnaire used for Step 1 evaluation (the same items are evaluated during Step 2). 
Intestinal Symptoms Baseline 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 
Abdominal pain or discomfort        
Heartburn        
Acid regurgitation        
Bloating        
Nausea and vomiting        
Borborygmus        
Abdominal distension        
Eructation        
Increased flatus        
Decreased passage of stools        
Increased passage of stools        
Loose stools        
Hard stools        
Urgent need for defecation        
Feeling of incomplete evacuation        
Extra-intestinal symptoms        
Dermatitis        
Headache        
Foggy mind        
Fatigue        
Numbness of the limbs        
Joint/muscle pains        
Fainting        
Oral/tongue lesions        
Other (specify)        
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Figure 1. The numerical rating scale (NRS) used for rating the intensity of relevant items. 
2.2. Step 2: the Gluten Challenge (Patient on the GFD) 
Step 2 is required to confirm the diagnosis of NCGS in patients responding to treatment with the 
GFD. A Double-Blind Placebo-Controlled Challenge with crossover presents a high level of evidence 
for diagnosing NCGS. Before starting the gluten challenge, the baseline diet needs to be strictly  
gluten-free to the level of a celiac diet for at least four weeks, i.e., no cross contamination, no gluten 
traces in the diet. The patient needs to be referred to a dietitian for assessment of the degree of the GFD. 
Two different types of challenge can be performed depending on the setting: (a) in clinical practice a 
single blinded procedure could be sufficient; (b) for research purposes, a double blind challenge remains 
the first choice. Provided there is marked improvement in symptoms with the GFD, the blinded 
challenges should be undertaken with care. For example, the gluten challenges may need to be repeated 
to offset the strong nocebo effect often seen in these patients. 
As far as the daily dose of gluten to be used for the challenge, we suggest an amount of 8 grams, a 
dose that is both close to the average daily intake of gluten in Western countries (10–15 g) [20] and easy 
to mix with the vehicle. This dose can be modulated in the research setting. As far as the gluten 
“vehicle”, gelatin capsules are discouraged. The best-suited vehicle is yet to be developed, for instance it 
could take form of a muesli bar, bread or muffin, possibly different in children and adults. The vehicle 
should contain cooked, homogeneously distributed gluten, and should be analyzed in order to know 
exactly the content of the pro-inflammatory factor ATIs. The gluten preparations should be 
prepared/tested for ATI bioactivity to contain at least 0.3 g of ATIs/8 g of gluten or gluten should be used 
with defined ATI content. The vehicle should be FODMAPs free. 
The placebo vehicle must be completely gluten-free. Gluten and placebo preparations must  
be undistinguishable in look, texture and taste, and balanced in fibers, carbohydrate, fat and possibly  
protein content. 
The gluten challenge includes a one-week challenge followed by a one-week washout of strict GFD 
and by the crossover to the second one-week challenge. The duration of the challenge period may 
occasionally be longer than a week in patients showing fluctuating symptoms, such as headache or 
neuro-behavioral problems. A questionnaire with the items shown in Table 2 is self-administered and 
filled in at baseline, and daily during the first seven-day challenge (or less if symptoms prevent 
completion of seven days), the washout period, and the second seven-day challenge (or less if symptoms 
prevent completion of seven days). During the challenge, the patient will identify and report one to three 
main symptoms, without necessarily filling in the full questionnaire. At least a variation of 30% between 
the gluten and the placebo challenge should be detected to discriminate a positive from a negative result. 
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The threshold of 30% increment in symptoms is somewhat arbitrary and needs scientific validation. 
Patients showing a negative gluten challenge should be investigated for other possible causes of IBS-like 
symptoms, e.g., intolerance to FODMAPs or small bowel bacterial overgrowth.  
A detailed flow diagram of the diagnostic process is shown in Figure 2. 
 
Figure 2. The flow diagram of the NCGS diagnostic process. GFD = gluten-free diet;  
A = product A (gluten or placebo); B = product B (placebo or gluten); E = evaluation 
(questionnaire). The evaluation is performed weekly during Step 1 and daily during Step 2. 
2.3. Monitoring the Gluten Elimination/Reintroduction Effects by Biomarkers 
Ideally the clinical evaluation performed during gluten elimination/reintroduction should include 
serially repeated specific laboratory tests. 
Although the most specific CD serological markers, such as IgA class anti-transglutaminase and  
anti-endomysial antibodies, are negative in NCGS patients by definition, IgG class antibodies directed 
against native gliadin (AGA) are found more frequently in these cases (about 50%) than in the general 
population, when eating a gluten-containing diet. Therefore, the finding of isolated IgG-AGA positivity 
may be a clue to the diagnosis of NCGS, particularly in subjects with extra-intestinal manifestations. 
When initially positive, IgG-AGA normalize more quickly in NCGS than CD patients after starting 
treatment with the GFD [21]. However, it is still unclear whether monitoring the levels of  
IgG-AGA may be helpful for diagnostic purposes during the rather short period of the gluten 
elimination/reintroduction challenge. 
The hypothesis of a “leaky gut” as a cause of neuropsychiatric disorders found indirect evidence from 
a study performed by the lactulose/mannitol (L/M) test, a simple clinical investigation exploring the 
usually divergent trans- and para-cellular permeability of the sugar probes. As a group, autistic children 
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on a regular diet tended to show higher values of the L/M intestinal permeability test when compared 
with autistic children on a GFD [15]. However, in a subsequent study, a four-week treatment with the 
GFD did not determine significant changes of the L/M test in a small group of children with autistic 
spectrum disorder [22]. No L/M test modification has been observed in adult patients affected with 
typical intestinal manifestations of NCGS [23]. For these reasons, the L/M test cannot be recommended 
for monitoring the gluten challenge. Recently, Hollon et al. investigated the intestinal permeability in 
human duodenal biopsies mounted in microsnapwells and luminally incubated with either gliadin or 
media alone. Changes in transepithelial electrical resistance (as an index of intestinal permeability) were 
monitored over 120 min. Following gliadin exposure, both patients with NCGS and those with active 
CD demonstrated a greater increase in intestinal permeability than celiacs in disease remission [24]. The 
clinical significance of these findings remains to be elucidated. 
The research on biological marker/s of NCGS is currently very active. Preliminary data observed in 
intestinal biopsies of NCGS patients showed an increase of intraepithelial lymphocytes (Marsh I) as well 
as the presence of markers associated with innate, rather than adaptive, immunity [2,23]. Recently, in an 
intestinal biopsy-based study, NCGS patients showed increased mucosal IFN-γ mRNA after a three-day 
gluten challenge [25]. Taken together these results suggest the presence of a mucosal immune activation 
in patients with NCGS. Therefore, the precise mechanisms underlying the induction of the immune 
response and the identification of reliable biomarkers for the diagnosis of NCGS are relevant issues that 
should be resolved. A search on www.clinicaltrials.gov performed on 2 January 2015 identified seven 
studies currently in progress to evaluate serological and mucosal indexes that could eventually find an 
application for diagnosing NCGS in clinical practice. 
3. Conclusions and Future Perspectives 
NCGS is a recently “re-discovered” clinical entity distinct from CD for which we have very little 
certainty and many knowledge “black holes”. NCGS was first described in the early 1980s [26], but over 
the past decade the number of patients diagnosed with NCGS and publications on this topic have 
increased greatly. However, it is still not clear how to diagnose and manage this condition, and the 
pathophysiological mechanisms are unclear. Therefore, in terms of knowledge, we are with NCGS now 
where we were with CD 40 years ago. Since we still do not have validated biomarker(s) for the diagnosis 
of NCGS, the diagnostic protocol remains cumbersome and not apt for large epidemiological studies 
aimed at establishing the prevalence of this condition. However specific diagnostic criteria for NCGS 
are necessary for optimizing clinical care, avoiding self-diagnosis and advancing the science of NCGS. 
The guidelines provided in this paper will (a) help the clinician to reach a firm and positive diagnosis of 
NCGS and (b) facilitate the comparisons of different studies, if adopted internationally. A more practical 
approach will only be possible with the development of biomarkers or other clinical predictors. 
The identification and validation of biomarker(s) will be instrumental to gain insights in NCGS 
pathogenesis, to establish the trigger(s) of this condition, and ultimately to establish the magnitude of 
this clinical condition. We will not be able to have a full understanding of NCGS until better diagnostic 
tools will become available and we have more information on NCGS pathogenesis, following the same 
path we followed during the last four decades of CD research. 
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